PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Ritu Salani, MD, MBA - Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence Sep 06, 2022

Show notes

Go online to PeerView.com/RXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView’s latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC. Upon completion of this activity, participants should be better able to: Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC; Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences; and Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research.

R. Sharon Chinthrajah, MD - IgE-Mediated Food Allergies: Improving Patient Quality of Life Through a Multidisciplinary Approach as a New Era of Treatment Dawns Sep 06, 2022

Show notes

Go online to PeerView.com/QER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current standards of care for managing food allergies require strict avoidance measures and prompt treatment of allergic reactions with emergency medications. However, oral immunotherapies and biologic agents are currently in development for the treatment of IgE-mediated food allergies, replacing the need for oral food challenges. Our expert faculty will share strategies for optimal clinical decision-making for patients with food allergy that is based on the latest evidence, best practice recommendations, and effective multidisciplinary collaboration. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of IgE-mediated food allergy and how these insights into underlying mechanisms can translate to the use of biomarkers to allow more personalized treatment for patients; Apply strategies to differentially diagnose patients with IgE-mediated food allergies using the latest criteria and expert recommendations; Identify patients with IgE-mediated food allergies who might be eligible for novel and emerging treatments and/or enrollment in clinical trials based on the latest evidence on efficacy and safety; and Employ a multidisciplinary approach to the treatment of patients with food allergy to optimize care and improve quality of life.

Sarah S. Chisolm, MD - Taking a New Look at Prurigo Nodularis: How Is Emerging Evidence Regarding Disease Pathophysiology and Treatment Influencing Patient Care? Sep 06, 2022

Show notes

Go online to PeerView.com/ZXX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) causes intensely itchy, painful bumps leading to scratching, bleeding, and thickening of the nodules, with negative effects on sleep, mental health, activities of daily living, social interaction, and quality of life. There are no approved treatments for PN, but several agents in late-stage clinical trials offer hope to patients with this burdensome disease. At a recent live PeerView MasterClass & Practicum, a panel of PN experts offered evidence-based, practical guidance on current diagnostic and treatment strategies and the latest clinical data regarding novel therapies. The discussion was enhanced by a 3D animation depicting PN pathophysiology and patient videos providing perspectives on the burdens of disease and treatment experience. Upon completion of this activity, participants should be better able to: Recognize how the signs and symptoms of prurigo nodularis (PN) impact patient quality of life; Explain how type 2 inflammation may play a role in the pathophysiology of PN; Describe current and emerging treatment options for PN in the context of mechanism of action, efficacy, and safety; and Develop individualized treatment plans for PN using currently available therapies and appropriately incorporating novel agents as they become available.

Wanda Phipatanakul, MD, MS - Controlling Moderate to Severe Asthma Across the Lifespan in an Ever-Evolving Treatment Landscape: How Much Do You Know? Sep 02, 2022

Show notes

Go online to PeerView.com/QYV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Asthma is a common, chronic, and heterogeneous disease that can result in poor quality of life and severe, life-threatening exacerbations despite standard controller therapy. Type 2 inflammation, mediated by cytokines such as IL-4, IL-5, and IL-13, occurs in about 50% of patients with asthma and has emerged as a unifying feature of classically defined allergic diseases and a range of other inflammatory diseases. In this activity, an expert explains the advances in understanding of the pathogenesis of asthma and the targeted treatments that have been developed as a result. You will hear expert insights into the use of available and emerging biologic therapies, including how to identify children and adults who may be eligible for these therapies. Upon completion of this activity, participants should be better able to: Identify patients who would likely benefit from targeted therapy, considering the relationship between type 2 inflammation, moderate to severe asthma, and comorbid conditions such as atopic dermatitis; Incorporate evidence-based and guideline-directed treatment for pediatric and adult patients with moderate to severe asthma into customized management plans; and Use techniques to educate and communicate with patients and caregivers to engage them in care and improve adherence to individualized treatment plans.

Cedric "Jamie" Rutland, MD - Addressing the Underlying Inflammation of Non–Cystic Fibrosis Bronchiectasis: Exploring Novel Treatments to Change Disease Course for Patients and Improve Quality of Life Sep 02, 2022

Show notes

Go online to PeerView.com/HTX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non-cystic fibrosis bronchiectasis is a long-term respiratory condition with a significant impact on quality of life, morbidity, mortality, and use of healthcare resources. The disease manifests as chronic airway inflammation, impaired mucociliary clearance, and structural lung damage leading to recurrent infections, persistent cough, sputum production, and exacerbations. The prevalence of bronchiectasis has been on the rise. Evolving insights into the pathophysiology of bronchiectasis have led to the development of novel and emerging agents to address the underlying inflammation, with the potential of changing the treatment landscape. In this animated activity, you will learn how to optimize clinical decision-making for patients with non-cystic fibrosis bronchiectasis that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Apply current guideline recommendations to the diagnosis and treatment of patients with bronchiectasis, with a goal of identifying and treating underlying causes; Describe the underlying mechanisms believed to contribute to inflammation in non–cystic fibrosis bronchiectasis and their correlation to emerging treatments; Assess recent clinical trial data concerning efficacy and safety of novel and emerging treatment options for non–cystic fibrosis bronchiectasis; and Develop strategies for preventing and treating exacerbations (eg, airway clearance, use of antibiotics, corticosteroids) in patients with non–cystic fibrosis bronchiectasis based on the latest expert recommendations using a personalized approach.

Anjali Tiku Owens, MD - Going Beneath the Surface of Hypertrophic Cardiomyopathy: Understanding the Pathophysiology and Deploying New Strategies for Timely Diagnosis and Targeted Treatment Sep 01, 2022

Show notes

Go online to PeerView.com/KHN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on hypertrophic cardiomyopathy (HCM) discusses guideline-recommended diagnostic approaches and therapeutic strategies to improve symptoms and preserve quality of life. Upon completion of this activity, participants should be better able to: Recognize the clinical characteristics and pathologic features suggestive of HCM; Differentially diagnose patients suspected of having HCM consistent with current guidance and evidence to promote early diagnosis and timely treatment; Assess the efficacy, safety, and ability of available therapeutic strategies to address the underlying pathophysiology and desired treatment goals; and Individualize treatment regimens for HCM consistent with patient preferences and goals of care.

Robert Sidbury, MD, MPH - Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis? Sep 01, 2022

Show notes

Go online to PeerView.com/WVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD); Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD; Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD; Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD; and Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects.

Rupa R. Patel, MD, MPH, DTM&H - A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care Aug 29, 2022

Show notes

Go online to PeerView.com/AHC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures. Upon completion of this activity, participants should be better able to: Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19; Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures; and Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team.

Julie V. Philley, MD; Kevin Winthrop, MD, MPH - Confronting the Challenges of Nontuberculous Mycobacterial Lung Disease: Expert Strategies for Reducing Diagnostic Delays and Improving Adherence to Guideline-Based Treatment Aug 29, 2022

Show notes

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Aditya Bardia, MD, MPH - Candid Conversations and Clinical Consults in Community Context: Practical Guidance for Integrating TROP2-Targeting ADCs Into Patient-Centric Breast Cancer Clinical Care Aug 29, 2022

Show notes

Go online to PeerView.com/JWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the management of patients with hormone receptor–positive breast cancer discuss the latest advances with TROP2-targeting antibody–drug conjugates (ADCs). Produced in collaboration with Living Beyond Breast Cancer and METAvivor, this program features a patient explaining her journey from diagnosis to participation in an important clinical trial, and faculty providing practical guidance for using TROP2-targeting ADCs in the individualized care of patients with breast cancer. Upon completion of this activity, participants should be better able to: Summarize the rationale, mechanism of action, and expanding clinical role of TROP2-targeting therapies in breast cancer; Integrate the latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Develop individualized management plans for patients with breast cancer that incorporate TROP2-targeting therapies using the latest clinical evidence and current practice guidelines to inform daily practice; and Apply a team-based approach to care that incorporates shared decision-making and patient counseling/education and leverages effective interprofessional collaboration and care coordination.

Our TOPPODCAST Picks

Follow Us

Stay Connected

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Related Podcasts

Links

Stay Connected